Long acting GLP-1 receptor agonist (injectable)
Semaglutide 2.0 mg subcutaneous once weekly
SEMA_SC_2p0MG_QW
Related
- All doses pooled: Semaglutide injection
- Semaglutide 1.0 mg subcutaneous once weekly
- Semaglutide maximum tolerated dose injection once weekly
- Semaglutide 2.4 mg subcutaneous once weekly
- Semaglutide 0.5 mg subcutaneous once weekly
- Semaglutide 0.5 mg injection
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.4 mg injection once daily
- Semaglutide 0.1 mg injection once daily
- Semaglutide 0.2 mg injection once daily
- Semaglutide 0.25 mg injection
- Semaglutide 1.5 mg injection once weekly
- Semaglutide 8 mg injection once weekly
- Semaglutide 16 mg injection once weekly
- Semaglutide 0.1072 mg injection
- Semaglutide 1.7 mg injection once weekly
- Semaglutide flexible dose injection once weekly
- Semaglutide 0.05 mg injection once daily
- Semaglutide 0.3 mg injection once daily
- Semaglutide flexible dose injection once weekly
- Semaglutide 2.4 mg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.52 (-0.91 to -0.12) | 0.77 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.81 (-2.67 to -0.97) | 0.79 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.79 (-1.34 to -0.22) | 0.65 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -6.41 (-9.36 to -3.49) | 0.85 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | MD -0.99 (-5.58 to 3.80) | 0.74 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | MD -0.97 (-5.87 to 4.17) | 0.85 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Semaglutide 1.0 mg subcutaneous once weekly | OR 1.52 (0.54 to 4.37) | 0.90 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.16 (0.02 to 1.25) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.65 (0.54 to 4.84) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.39 (0.07 to 24.32) | 0.42 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 8.47 (1.05 to 29.37) | 0.89 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Semaglutide 1.0 mg subcutaneous once weekly | OR 1.34 (0.52 to 3.36) | 0.95 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 3.61 (1.15 to 6.18) | 0.98 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.96 (0.60 to 1.53) | 0.51 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 3.10 (0.98 to 12.11) | 0.30 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.11 (1.94 to 4.94) | 0.44 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.85 (2.26 to 6.75) | 0.38 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.77 (1.18 to 2.72) | 0.45 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.36 (1.24 to 10.89) | 0.24 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 3.35 (0.58 to 24.16) | 0.35 |
| Type 2 diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 2.33 (0.29 to 19.86) | 0.34 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.29 (0.04 to 2.01) | 0.71 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.41 (0.01 to 16.45) | 0.66 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.26 (0.00 to 8.04) | 0.65 |
Trials
- S00300231 randomized · 36 weeks
- NCT05514535Efficacy and Safety of Once-weekly Semaglutide S.C. 2.0 mg as Add-on to Dose-reduced Insulin Glargine vs Titrated Insulin Glargine in Participants With Type 2 Diabetes and Overweight2022 · 573 randomized · 40 weeks
- NCT05486065Investigation of Once-weekly Semaglutide S.C. Dose-Response in Patients With Type 2 Diabetes and Overweight - a Participant- and Investigator-blinded and Sponsor Open-label Study2022 · 245 randomized · 40 weeks
- SUSTAIN FORTEEfficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes2019 · 961 randomized · 40 weeks